UBS has reiterated its "Buy" rating for Merck KGaA, with a target price of 190 euros ahead of the Group's Capital Markets Day.
Analyst Matthew Weston stated that the new targets released by the chemicals and pharmaceuticals company were previously indicated and closely align with consensus estimates.
The report, published on October 17, 2024, emphasizes the positive outlook for Merck KGaA, reflecting confidence in the company's strategic direction and financial performance.
Investors are advised to consider the stock as it continues to meet market expectations.